Low/low class (n = 53) | Middle class (n = 183) | High/high class (n = 71) | p Value | |
---|---|---|---|---|
Serum infliximab level, μg/ml | ||||
Week 2 | 13.9 (12.0, 15.7) | 13.2 (10.2, 16.3) | 12.0 (9.5, 14.2) | 0.0028 |
Week 6 | 7.6 (4.5, 10.8) | 7.1 (2.5, 10.0) | 5.0 (1.6, 8.2) | 0.0072 |
Week 10 | 7.7 (3.9, 10.5) | 6.3 (2.0, 10.3) | 3.8 (1.5, 7.9) | 0.0040 |
Week 14 | 1.5 (0.6, 2.1) | 0.7 (<0.1, 2.0) | 0.4 (<0.1, 1.1) | 0.0014 |
Week 14, < 0.1/≥ 0.1 to < 0.1/≥ 1.0 | 13%/25%/62% | 33%/25%/42% | 32%/38%/30% | 0.0015 |
DAS28-CRP | ||||
Week 2 | 3.89 (3.09, 4.51) | 3.90 (3.24, 4.52) | 4.01 (3.34, 4.79) | 0.2770 |
Week 6 | 3.32 (2.78, 4.16) | 3.42 (2.67, 4.22) | 3.68 (2.96, 4.36) | 0.2381 |
Week 10 | 3.19 (2.57, 3.77) | 3.24 (2.55, 4.12) | 3.48 (2.67, 4.20) | 0.3612 |
Week 14 | 3.17 (2.49, 3.69) | 3.53 (2.63, 4.36) | 3.82 (2.62, 4.97) | 0.0764 |
Week 14, REM/LDA/MDA/HDA | 17%/15%/51%/17% | 15%/12%/40%/33% | 18%/10%/31%/41% | 0.1455 |